Atomwise Stock

Atomwise, a company leveraging AI and machine learning to accelerate drug discovery, has raised $123 million in venture capital.

The folks behind Atomwise's spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures